Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Détails

ID Serval
serval:BIB_A4B7EE94B270
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.
Périodique
Frontiers in Bioscience
Auteur⸱e⸱s
Ruter J., Barnett B.G., Kryczek I., Brumlik M.J., Daniel B.J., Coukos G., Zou W., Curiel T.J.
ISSN
1093-4715 (Electronic)
ISSN-L
1093-4715
Statut éditorial
Publié
Date de publication
2009
Volume
14
Pages
1761-1770
Langue
anglais
Notes
Publication types: Journal Article ; ReviewPublication Status: epublish
Résumé
Cancers express tumor associated antigens that should elicit immune attack, but spontaneous immune rejection of established cancer is rare. Recent data demonstrate that specific and active tumor-mediated mechanisms hinder host anti-tumor immunity. CD4+CD25+ T regulatory cells (Tregs) are important mediators of active immune evasion in cancer. Disrupting tumor-mediated mechanisms hindering host immunity is a novel approach to tumor immunotherapy. Treg depletion improves endogenous anti-tumor immunity and the efficacy of active immunotherapy in animal models for cancer, suggesting that inhibiting Treg function could also improve the limited successes of human cancer immunotherapy. We have identified five strategies to block Treg activity: depletion, interference with trafficking, inhibition of differentiation, blockade of function or raising the effector T cell threshold for suppression. Discovery of additional regulatory cell populations expands the potential targets for these approaches. The fusion toxin denileukin diftitox (Ontak) reduces Treg numbers and function in the blood of some patients with cancer. We discuss specific strategies to block Treg activity and present some of our preliminary data in this area. Combining Treg depletion with active vaccination and other approaches poses additional challenges that are discussed.
Mots-clé
Cancer Vaccines/therapeutic use, Cell Differentiation, Humans, Immunotherapy, Neoplasms/immunology, Neoplasms/pathology, T-Lymphocytes, Regulatory/cytology, T-Lymphocytes, Regulatory/immunology
Pubmed
Web of science
Création de la notice
14/10/2014 12:43
Dernière modification de la notice
20/08/2019 16:10
Données d'usage